American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.
By G. Lyman, A. Giuliano, M. Somerfield, A. Benson, D. Bodurka, H. Burstein, A. Cochran, H. Cody, S. Edge, S. Galper and 10 more. Journal of Clinical Oncology, 2005
1,859 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/ef6a1baa9441a4ebc4a5fb90f8c64ff67a61b288
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Pathology and Forensic Medicine
Citations in the corpus
- Deep Learning for Identifying Metastatic Breast Cancer (2016, background): “The evaluation of breast sentinel lymph nodes is an important component of the American Joint Committee on Cancer’s TNM breast cancer staging system, in which patients with a sentinel lymph node positive for metastatic cancer will receive a higher pathologic TNM stage than patients negative for sent”
- Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial (2010, background): “However, most consensus statements including one from the American Society of Clinical Oncology recommend ALND for patients whose SN contains macrometastases, ITCs, or micrometastases.(4,5) A number of reports have suggested that selected patients with SN metastasis may be managed without completion”